Chimeric Antigen Receptor T-Cells: The Future Is Now

被引：25
作者：
Mchayleh, Wassim [1 ]
Bedi, Prabhjot [2 ]
Sehgal, Rajesh [2 ]
Solh, Melhem [1 ,3 ]
机构：
[1] Northside Hosp Canc Inst, Dept Med, Atlanta, GA 30342 USA
[2] Univ Pittsburgh Ctr East, Dept Med, Monroeville, PA 15146 USA
[3] Northside Hosp, Blood & Marrow Transplant, Acute Leukemia & Immunotherapy Program, Atlanta, GA 30342 USA
来源：
JOURNAL OF CLINICAL MEDICINE | 2019年 / 8卷 / 02期
关键词：
Chimeric; cellular; immunotherapy; T cell; ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL; IMMUNOTHERAPY; REGRESSION; CHILDREN; ADULTS; ACTIVATION; MANAGEMENT; THERAPY; CARS;
D O I：
10.3390/jcm8020207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The immune system acting via cancer immune-surveillance is considered a potential target for improving outcomes among some malignancies. The ability to harness immune cells, engineer them and educate them to target cancer cells has changed the paradigm for treating non-Hodgkin's lymphomas (NHL) and acute lymphoblastic leukemia (ALL). Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable anti-tumor activity against refractory B cell malignancies. Ongoing research aims to expand the scope of this adoptive cell therapy, understanding mechanisms of resistance and reducing toxicity. In this review, we will discuss the current scope of CAR T-cell therapy and ongoing future applications.
引用
收藏
页数：10
相关论文
共 61 条
[1]   Regression of experimental medulloblastoma following transfer of HER2-specific T cells [J].
Ahmed, Nabil ;
Ratnayake, Maheshika ;
Savoldo, Barbara ;
Perlaky, Laszlo ;
Dotti, Gianpietro ;
Wels, Winfried S. ;
Bhattacharjee, Meenakshi B. ;
Gilbertson, Richard J. ;
Shine, H. David ;
Weiss, Heidi L. ;
Rooney, Cliona M. ;
Heslop, Helen E. ;
Gottschalk, Stephen .
CANCER RESEARCH, 2007, 67 (12) :5957-5964
[2]   CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells [J].
Alcantara, Marion ;
Tesio, Melania ;
June, Carl H. ;
Houot, Roch .
LEUKEMIA, 2018, 32 (11) :2307-2315
[3]  
[Anonymous], 2015, BLOOD
[4]   CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum [J].
Bagashev, Asen ;
Sotillo, Elena ;
Tang, Chih-Hang Anthony ;
Black, Kathryn L. ;
Perazzelli, Jessica ;
Seeholzer, Steven H. ;
Argon, Yair ;
Barrett, David M. ;
Grupp, Stephan A. ;
Hu, Chih-Chi Andrew ;
Thomas-Tikhonenko, Andrei .
MOLECULAR AND CELLULAR BIOLOGY, 2018, 38 (21)
[5]   Toxicity and management in CAR T-cell therapy [J].
Bonifant, Challice L. ;
Jackson, Hollie J. ;
Brentjens, Renier J. ;
Curran, Kevin J. .
MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16011
[6]  
Bot A, 2015, ASH ANN M ABTR, V126, P4426
[7]   Chimeric Fv-ξ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells [J].
Brocker, T .
BLOOD, 2000, 96 (05) :1999-2001
[8]   Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy [J].
Brown, Christine E. ;
Alizadeh, Darya ;
Starr, Renate ;
Weng, Lihong ;
Wagner, Jamie R. ;
Naranjo, Araceli ;
Ostberg, Julie R. ;
Blanchard, M. Suzette ;
Kilpatrick, Julie ;
Simpson, Jennifer ;
Kurien, Anita ;
Priceman, Saul J. ;
Wang, Xiuli ;
Harshbarger, Todd L. ;
D'Apuzzo, Massimo ;
Ressler, Julie A. ;
Jensen, Michael C. ;
Barish, Michael E. ;
Chen, Mike ;
Portnow, Jana ;
Forman, Stephen J. ;
Badie, Behnam .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) :2561-2569
[9]   Toxicities of chimeric antigen receptor T cells: recognition and management [J].
Brudno, Jennifer N. ;
Kochenderfer, James N. .
BLOOD, 2016, 127 (26) :3321-3330
[10]   T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma [J].
Chow, Kevin K. H. ;
Naik, Swati ;
Kakarla, Sunitha ;
Brawley, Vita S. ;
Shaffer, Donald R. ;
Yi, Zhongzhen ;
Rainusso, Nino ;
Wu, Meng-Fen ;
Liu, Hao ;
Kew, Yvonne ;
Grossman, Robert G. ;
Powell, Suzanne ;
Lee, Dean ;
Ahmed, Nabil ;
Gottschalk, Stephen .
MOLECULAR THERAPY, 2013, 21 (03) :629-637
1234567